MICA and neoplasm: The mesoporous silica rod scaffold vaccine containing polyvalent protein antigen, GM‐CSF, and the adjuvant CpG ODN 1826 resulted in robust generation of MICA/B antibodies, blocking proteolysis of surface‐associated MICA/B and enabling elimination of tumor cells.